Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

PURPOSE: Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to bortezomib and dexamethasone. This phase I, dose-escalation study (ie, NCT00153933) evaluated safety and determined the maximum-toler...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Richardson, Paul G., Weller, Edie, Jagannath, Sundar, Avigan, David E., Alsina, Melissa, Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Ghobrial, Irene M., Doss, Deborah, Warren, Diane L., Lunde, Laura E., McKenney, Mary, Delaney, Carol, Mitsiades, Constantine S., Hideshima, Teru, Dalton, William, Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2009
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2799050/
https://ncbi.nlm.nih.gov/pubmed/19786667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.2679
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky